Drotrecogin alfa (activated): Down and not out, but not really in either

Critical Care

Volumn 10, Issue 5, 2006, Pages

  Friedrich, Jan O ^a   Adhikari, Neill K J ^b   Meade, Maureen O ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

APACHE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; LETTER; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; STATISTICAL MODEL; NOTE;

HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 34249029319     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5022     Document Type: Letter

References (8)

1. Agarwal R Nath A Activated protein C in sepsis: Down but not out, yet Crit Care 2006 10 416 10.1186/cc4988 16887006 1750980
2. Friedrich JO Adhikari NK Meade MO Drotrecogin alfa (activated): Does current evidence support treatment for any patients with severe sepsis? Crit Care 2006 10 145 1550958 16762040 10.1186/cc4947
3. Abraham E Laterre PF Garg R Levy H Talwar D Trzaskoma BL Francois B Guy JS Bruckmann M Rea-Neto A for the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 2005 353 1332-1341 10.1056/NEJMoa050935 16192478
4. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand D Ely EW for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001 344 699-709 10.1056/ NEJM200103083441001 11236773
5. Higgins JP Thompson SG Deeks JJ Altman DG Measuring inconsistency in meta-analyses BMJ 2003 327 557-560 192859 12958120 10.1136/ bmj.327.7414.557
6. Ely EW Laterre PF Angus DC Bernard GR Drotrecogin alfa (activated) administration: Too many subgroups [Letter] Crit Care Med 2003 31 2564-2565 10.1097/00003246-200301000-00002 14530774
7. Ely EW Laterre PF Angus DC Helterbrand JD Levy H Dhainaut JF Vincent JL Macias WL Bernard GR PROWESS Investigators Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit Care Med 2003 31 12-19 10.1097/ 00003246-200301000-00002 12544987
8. Schultz MJ Levi M Prescription of rh-APC differssubstantially among western European countries Intensive Care Med 2006 32 630-631 10.1007/ s00134-006-0075-z 16520998